Dr. Kelley’s lab at University of Toronto is focused on building biomolecular sensors and conducting rare/single cell analysis. She has published over 200 scientific papers cited over 18,000 times. Kelly is a recognized expert in translating research discoveries into successful commercial ventures. In 2019, Kelley founded Cellular Analytics, a company that is developing a novel liquid biopsy, which can report on the phenotypic properties of tumors and metastatic disease. Dr. Kelley’s outstanding work has been recognized by a variety of awards, including an ACS Nanoscience Award, the 2016 SLAS Innovation award, an NSERC Brockhouse Award, the 2011 Steacie Prize, an Alfred P. Sloan Research Fellowship, and the Camille Dreyfus Teacher-Scholar award. She has been named one of ‘Canada’s Top 40 under 40’ by The Globe & Mail and a “Top 100 Innovator” by MIT’s Technology Review. Before Cellular Analytics, Kelley founded two biotechnology start ups, GeneOhm Sciences and Xagenic, the former which was successfully acquired by Becton Dickinson in 2005.
Liquid Biopsy Showcase:
Cellular Analytics develops tools that detect and profile surface proteins on rare cells in the blood. Our proprietary microfluidic platform, CytoFind™, has shown high sensitivity and specificity in capturing circulating tumor cells, which are further analyzed to predict patient response to therapy.
Detecting Circulating Tumor Cells Using CytoFind™
The PMWC 2022 Liquid Biopsy Showcase will provide a 15-minute time slot for selected liquid biopsy companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies that advance the development of screening tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).